C2 PHARMA, a company that manufactures and supplies ophthalmic and niche active pharmaceutical ingredients (APIs), reported the approval of a C-Drug Master Filing (DMF) for Digoxin, an API manufactured by its Polish manufacturing partner Nobilus Ent. The milestone comes after what the company calls, a challenging three-year journey, due to global disruptions caused by the Covid pandemic. The approval covers both Digoxin and Digoxin micronized. It supports different dosage forms i.e., oral, an...